Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Neoplasm Metastasis 8Lung Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Ovarian Neoplasms 5Melanoma 5Carcinoma, Renal Cell 5Skin Neoplasms 4Fallopian Tube Neoplasms 4Carcinoma 4Triple Negative Breast Neoplasms 3Recurrence 3Prostatic Neoplasms 3Mouth Neoplasms 3Colorectal Neoplasms 3Breast Neoplasms 3Adenocarcinoma 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Laryngeal Neoplasms 2Head and Neck Neoplasms 2Endometrial Neoplasms 2

Interventions

cemiplimab 1alpha-2'-deoxythioguanosine 1Vinorelbine 1Gemcitabine 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Large Cell × cemiplimab × Clear all
NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Maia Biotechnology

Phase 3 Recruiting
300 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡